Next Issue
Volume 7, 08
Previous Issue
Volume 7, 05
 
 
cardiovascmed-logo

Journal Browser

Journal Browser
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).

Cardiovasc. Med., Volume 7, Issue 6 (06 2004) – 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
2 pages, 142 KB  
Interesting Images
Akute Dyspnoe bei chronischem Vorhofflimmern
by Peter Eichhorn
Cardiovasc. Med. 2004, 7(6), 269; https://doi.org/10.4414/cvm.2004.01031 - 30 Jun 2004
Viewed by 39
Abstract
Eine 67jährige Patientin leidet seit 16 Monaten infolge einer hypertensiven Herzkrankheit an einem tachykarden Vorhofflimmern, das weder auf Sotalol noch Amiodarone in einen Sinusrhythmus konvertiert werden konnte [...] Full article
Show Figures

Figure 1

8 pages, 167 KB  
Editorial
Direkte Orale Thrombinhemmung Mit Ximelagatran
by Pascal Koepfli and Jürg H. Beer
Cardiovasc. Med. 2004, 7(6), 261; https://doi.org/10.4414/cvm.2004.01036 - 30 Jun 2004
Viewed by 40
Abstract
Ximelagatran is the first direct oral thrombin inhibitor likely to receive approval for clinical use in the near future. Efficacy and risk of bleeding in the settings of postoperative prophylaxis, treatment and secondary prevention of venous thromboembolism as well as prevention of stroke [...] Read more.
Ximelagatran is the first direct oral thrombin inhibitor likely to receive approval for clinical use in the near future. Efficacy and risk of bleeding in the settings of postoperative prophylaxis, treatment and secondary prevention of venous thromboembolism as well as prevention of stroke in patients with atrial fibrillation appear comparable with the benefits of heparins and coumarins. Advantages are mainly based on the predictable pharmacodynamic and -kinetic properties including a favourable therapeutic window and low potential for interactions with food or co-medication which appears to make monitoring unnecessary. Existing concerns are related to the (mostly transient) increase in concentration of alanine aminotransferase in the serum in approximately 7% of patients, the management of major bleeding and the interaction with preexisting liver and kidney disorders. Full article
Show Figures

Figure 1

3 pages, 121 KB  
Case Report
Percutaneous Left Ventricular Assist Device to Support PCI of Unprotected Left Main Coronary Artery Disease
by Stéphane Cook, Bernhard Meier and Stephan Windecker
Cardiovasc. Med. 2004, 7(6), 258; https://doi.org/10.4414/cvm.2004.01030 - 30 Jun 2004
Viewed by 35
Abstract
Introduction. Although percutaneous coronary intervention (PCI) has long surpassed coronary artery bypass grafting (CABG) as the most common revascularization strategy in patients with coronary artery disease [...] Full article
Show Figures

Figure 1

9 pages, 183 KB  
Editorial
Myokarditis: Diagnostik und Verlauf
by Barbara Naegeli
Cardiovasc. Med. 2004, 7(6), 248; https://doi.org/10.4414/cvm.2004.01035 - 30 Jun 2004
Viewed by 42
Abstract
The term “myocarditis” is applied to a variety of inflammatory disorders affecting the myocardium. Because of a wide spectrum of clinical manifestations ranging from asymptomatic to frank circulatory failure little is known about the epidemiological aspects of the disease. Based on the initial [...] Read more.
The term “myocarditis” is applied to a variety of inflammatory disorders affecting the myocardium. Because of a wide spectrum of clinical manifestations ranging from asymptomatic to frank circulatory failure little is known about the epidemiological aspects of the disease. Based on the initial presentation four typical clinical syndromes can be distinguished: 10––30% of patients experience acute chest pain indistinguishable from an acute coronary syndrome, 60––70% present with congestive heart failure, in 5––15% arrhythmias might be among the first complaints and 5––10% present with fulminant cardiogenic shock. Thus it is important to rule out other confounding cardiac disorders during the initial diagnostic work-up. In the following review we propose a pragmatic approach to the diagnostic work-up of myocarditis according to the presenting manifestations. The range of the clinical course is also highly variable, notably up to 60% of cases of myocarditis undergo a full recovery, whereas on the other hand progressive pump failure might require a rapid intervention including mechanical circulatory assistance. Interestingly the clinical presentation and symptoms at onset are predictive for the further course and outcome. Further research in basic and clinical science is warranted in the search for an effective treatment and understanding of this challenging disorder. Full article
Show Figures

Figure 1

8 pages, 212 KB  
Article
Die Wissenschaftliche Produktivität in der Schweiz
by Christoph J. Fahrni, J. P. Hellermann and T. F. Lüscher
Cardiovasc. Med. 2004, 7(6), 238; https://doi.org/10.4414/cvm.2004.01032 - 30 Jun 2004
Cited by 1 | Viewed by 43
Abstract
The activity of scientists aims for new knowledge, in medicine particularly about illnesses, their aetiology, diagnosis and, of course, therapy. The success of scientific activity can be measured, for instance, by the quantity and quality of publications, as well as by their effect [...] Read more.
The activity of scientists aims for new knowledge, in medicine particularly about illnesses, their aetiology, diagnosis and, of course, therapy. The success of scientific activity can be measured, for instance, by the quantity and quality of publications, as well as by their effect on specialised literature, and by their consequences in clinical practice. The main objective of this study was to establish an overview of the productivity and the success of cardiological research in Switzerland by analysing its publication output. All members of the Swiss Society of Cardiology and, for comparison, of the Swiss Society for Oncology were included in this study. All publications dating from 1986 to 2000 by these authors were recorded, including their impact factor and citation index. In both cardiology and oncology, the number of publications has steadily increased over the years. The highest number of publications in both fields originated from the germanspeaking part of Switzerland, followed by the french-speaking region. Throughout, more articles were published on cardiological themes, the exception being the italian-speaking part of Switzerland, which produced more papers regarding oncological themes than cardiological ones. The comparison of universities showed Zurich publishing the most in cardiology, followed by Berne, Lausanne, Geneva and Basel, while in oncology the leading university in terms of number of publications was Berne, followed by Basel, Zurich, Geneva and Lausanne. The average impact factor of a publication in cardiology was 4.1, slightly higher than in oncology (3.9). On average however, oncological publications were cited more often (13.4 vs. 12.9; p ≤ 0.001). The highest citation count of a single publication was 1855 in cardiology, 437 in oncology. 35.7% of publications in cardiology and 30.3% in oncology were never cited. The number of total citations for an individual scientist ranged from 0 to 14,642 in cardiology, and from 0 to 4698 in oncology. The analysis of scientific productivity of two comparable fields of research in Switzerland, and the regional and individual differences shown, might be of value for future evaluations of scientists, groups and institutions and, as a consequence, be taken into consideration for the allocation of funds and resources. Full article
Show Figures

Figure 1

4 pages, 128 KB  
Editorial
Wie gut ist die Schweiz?
by Thomas F. Lüscher
Cardiovasc. Med. 2004, 7(6), 233; https://doi.org/10.4414/cvm.2004.01033 - 30 Jun 2004
Cited by 1 | Viewed by 34
Abstract
Dass Erfolg gemessen wird und auch gemessen werden will, daran haben sich Sportler längst gewöhnt [...] Full article
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop